Uveitis Treatment Market By Disease Type (Intermediate Uveitis, Posterior Uveitis, Anterior Uveitis, Panuveitis); By Cause (Noninfectious, Infectious); By Treatment Type (Monoclonal Antibodies, Cycloplegic Agents, Corticosteroids, Immunosuppressant, Antibiotics, Antifungal, Antivirals, Analgesics, Others); By Distribution Channel (Retail, Hospital, Online, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity and Forecast, 2022-2032
Uveitis Treatment Market Highlights
Uveitis Treatment Market size was valued at USD 0.6 billion in 2022, and is projected to reach USD 1.1 billion by 2032, growing at a CAGR of 5.90% from 2022 to 2032.
Uveitis Treatment Market Definition and Overview
Uveitis, an autoimmune eye disease is the internal inflammation of the uvea or the uveal tract, the layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea comprises of the ciliary body, iris, and choroid.
Uveitis is caused due to infection with a virus, fungus, bacteria, parasite, injuries and other inflammatory disease. Usual symptoms related to uveitis which directly affects the eye include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye. It can lead to poor vision or complete blindness both to humans as well as animals. Therefore, it is an ophthalmic emergency and requires urgent treatment to control the inflammation.
Corticosteroid is typically deemed to be the first-line therapy for the treatment of uveitis. Also, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics along with various other drug formulations are used for the treatment of uveitis.
Uveitis Treatment Market : Report Scope |
|
|
Base Year Market Size |
2021 |
|
Forecast Year Market Size |
2022-2032 |
|
CAGR Value |
5.90% |
|
Segmentation |
|
|
Challenges |
|
|
Growth Drivers |
|
Uveitis Treatment Market Drivers
The growth of this market is attributed towards major pertaining factors including; the rising prevalence of uveitis and related complications worldwide, the high occurrence of autoimmune disorders globally, the upsurge in the development of biological drugs for the treatment of uveitis, the spurring demand for advanced healthcare products, the rising number of government initiatives to minimize eye disorders coupled with the presence of grants and fellowships, the growing popularity of advanced therapeutics, and the robust development of healthcare infrastructure in various developing nations etc.
Additionally, the ophthalmological sector has been witnessing enormous traction in the research and development activities recently for new drug discovery also leading to development of ideal therapeutics. Increasing amount of investments for R&D activities is giving rise to more and more clinical studies being performed for treating eye inflammation globally. A lot of new stage III clinical trials for refractory post or intermediate uveitis are currently under development. This is creating ample opportunities for the growth of the uveitis treatment market.
Moreover, the affluent market players present in the market are seen to be emphasizing on making technological advancements and introducing new and innovative products into the market rapidly. As a result, novel drug formulations which can reduce uveitis and allow ophthalmologist to offer improved ophthalmic treatment and patient care are being extensively developed. This also leads to improved efficiency and safety profiles in the clinical trial stage of development, thereby reducing the progression of disease considerably. For instance, players in uveitis treatment are focusing on introducing steroid implants, which is proving out to be rigorously accepted for drug delivery in case of noninfectious posterior uveitis and also adjuvant immunosuppressing agents which have proven to be efficient in the recent past.
Furthermore, other factors such as the growing geriatric populace, the fast-track approval of pipeline drugs, the increasing disposable incomes of people coupled with high expenditure on healthcare and the increasing number of clinical trials for eye inflammation treatment are further enhancing the growth of the market.. Also, the increasing numbers of hospitals, diagnostic centers, online treatments is also contributing massively in fueling the growth of the uveitis treatment market.
However, factors such as the adverse effects related to uveitis treatment medication such as watery eyes etc., the high cost associated with treatment, the poor primary healthcare infrastructure, the absence of awareness about eye disorders, the unavailability of health insurance in developing countries, lack of skilled professionals and the unknown etiology and pathophysiology of uveitis, hinder the growth of this market.
Uveitis Treatment Market Challenges
The uveitis treatment market faces several challenges, including:
- Lack of diagnostic tools: Uveitis can be difficult to diagnose, and there is a lack of effective diagnostic tools available. This can lead to delayed or incorrect treatment and can result in serious vision loss.
- Limited availability of effective treatments: There are limited options for the treatment of uveitis, and some of the available treatments are not effective for all patients. This can lead to frustration and dissatisfaction among patients and healthcare providers.
- High cost of treatment: Many of the available treatments for uveitis are expensive, and this can be a major barrier to access for many patients, especially in developing countries.
- Side effects of treatment: Some of the treatments for uveitis can cause significant side effects, including vision loss, cataracts, and glaucoma. This can limit their use and impact their effectiveness.
- Resistance to treatment: Some patients may develop resistance to certain treatments over time, making it difficult to manage their condition effectively.
- Lack of awareness: Uveitis is a relatively unknown condition, and there is a lack of awareness about the condition and its treatment options among patients and healthcare providers. This can make it difficult for patients to access the care they need.
- Regulatory hurdles: The approval process for new treatments for uveitis can be lengthy and complex, with many regulatory hurdles to overcome. This can limit the development and availability of new treatments for the condition.
Uveitis Treatment Market Regional Outlook
The North American region is the most prominent and the largest regional market for uveitis treatment followed by Europe. The region is anticipated to maintain its position at the top in the upcoming years also on account of various factors such as; the increasing incidence of infectious uveitis and related disorders in the region, the early approval of pipeline drugs as compared to other regions in the region, the advanced healthcare infrastructure in the region, the increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids, the high patient awareness levels about eye disorders and the favorable refund policies available in the region etc. The major contributors in the region include the U.S and Canada.
The European region is the second largest market for uveitis treatment and the same is anticipated to witness substantial growth in the forthcoming years. The growth in the region can be attributed to factors such as the growing prevalence of autoimmune disorders such as AIDS and multiple sclerosis in the region, the growing R&D initiatives and activities in the region, the rising incidence of eye diseases in the region, the active conducting of clinical trials in the region as well as rising healthcare expenditure in this region etc. The major contributors in the region are Germany, France and the U.K.
The Asia Pacific region is the third largest and the fastest growing regional market for uveitis treatment. The region is set to continue to experience growth at a substantial rate in the upcoming years owing to factors such as the growing prevalence of patients affected with uveitis in the region, the absence of sanitation of infectious illnesses in the developing countries in the region, the increasing awareness regarding different therapy options available in the region and the rising government initiatives to curtail eye disorders in the region. Additionally, the increasing aging population, the growing disposable incomes of people in the region and the developing medical infrastructure in the region also contribute significantly in the growth of this uveitis treatment regional market. The major contributors in the region include India, Japan and China. Countries such as Singapore and South Korea are also looking to gain momentum and are contributing to the growth significantly since the past years.
Uveitis Treatment Market Segmentation
By Disease Type
- Intermediate Uveitis
- Posterior Uveitis
- Anterior Uveitis
- Panuveitis
By Cause
- Noninfectious
- Infectious
By Treatment Type
- Monoclonal Antibodies
- Cycloplegic Agents
- Corticosteroids
- Immunosuppressant
- Antibiotics
- Antifungal
- Antivirals
- Analgesics
- Others
By Distribution Channel
- Retail
- Hospital
- Online
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Uveitis Treatment Market Key Players
- Bausch & Lomb Incorporated
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Alimera Sciences Inc
- Amgen Inc.
- Clearside Biomedical Inc.
- EyePoint Pharmaceuticals Inc.
- Mylan N.V.
- Ophthalix Inc.
- Santen Pharmaceutical Co. Ltd.
- Topivert Ltd.
- HANALL
- Regeneron Pharmaceuticals Inc.
- XOMA
- pSivida Corp.
- Allergan India Private Limited
- Enzo Biochem Inc.
- AbbVie Inc.
- Other Players
Uveitis Treatment Drugs
Uveitis is a condition that causes inflammation of the uvea, a part of the eye. There are several drugs that are used to treat uveitis, including:
- Corticosteroids: Corticosteroids are the most commonly used drugs for the treatment of uveitis. They are effective in reducing inflammation and can be administered orally, topically, or by injection.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs, such as indomethacin and diclofenac, can be used to treat uveitis. They work by blocking the production of prostaglandins, which are substances that cause pain and inflammation.
- Immunosuppressive drugs: Immunosuppressive drugs, such as methotrexate, azathioprine, and cyclosporine, are used to suppress the immune system and reduce inflammation. They are typically used in cases of severe or refractory uveitis.
- Biologic agents: Biologic agents, such as tumor necrosis factor (TNF) inhibitors, are a newer class of drugs used to treat uveitis. They work by blocking specific proteins involved in the immune response and are used in cases of severe or refractory uveitis.
- Antifungal and antiviral drugs: Antifungal and antiviral drugs may be used to treat uveitis that is caused by an underlying infection.
The choice of drug and treatment regimen will depend on several factors, including the underlying cause of the uveitis, the severity of the inflammation, and the patient's overall health. It is important for patients to work closely with their healthcare provider to determine the best course of treatment for their individual needs.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
- Publication date: 23rd January 2024
- Base year: 2022
- Forecast year: 2023-2033
- Format: PDF, PPT,Word,Excel
- Quick Contact -
- ISO Certified Logo -
Frequently Asked Questions(FAQ)
Uveitis Treatment Market
-: Our Clients :-
